Mayne Pharma Group Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Mayne Pharma Group şirketinin kazançlarının yıllık 57.5% oranında düşmesi, yıllık gelirinin ise yıllık 1.1% oranında artması bekleniyor. EPS'nin yıllık 60.5% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-57.5%

Kazanç büyüme oranı

-60.53%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	45.8%
Gelir büyüme oranı	1.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	27 Aug 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Yeni Anlatı • Jul 17

Women’s Health Expansion And Manufacturing Upgrade Will Support Stronger Long-Term Earnings Potential

Catalysts About Mayne Pharma Group Mayne Pharma Group is a specialty pharmaceutical company focused on Women's Health, Dermatology and International markets. What are the underlying business or industry changes driving this perspective?

Yeni Anlatı • Jul 02

Rising Women's Health Costs And Flat Revenue Will Eventually Reveal Underappreciated Earnings Potential

Catalysts About Mayne Pharma Group Mayne Pharma Group is a pharmaceutical company focused on Women's Health, Dermatology and International markets, with an emphasis on branded products and specialized distribution models. What are the underlying business or industry changes driving this perspective?

Anlatı Güncellemesi • Jul 02

None

Analysts have reduced their price target for Mayne Pharma Group from A$5.75 to A$4.62, citing updated assumptions that pair a lower revenue growth outlook with a slightly higher discount rate. This is partly offset by a firmer profit margin and a lower future P/E multiple.

Yeni Anlatı • May 01

Women’s Health Trends And Dermatology Platform Will Reshape Long-Term Earnings Profile

Catalysts About Mayne Pharma Group Mayne Pharma Group focuses on branded and specialty pharmaceutical products in Women's Health, Dermatology and International markets. What are the underlying business or industry changes driving this perspective?

Analiz Makalesi • Feb 13

Mayne Pharma Group Limited (ASX:MYX) Held Back By Insufficient Growth Even After Shares Climb 26%

Mayne Pharma Group Limited ( ASX:MYX ) shareholders would be excited to see that the share price has had a great month...

Analiz Makalesi • Sep 01

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Mayne Pharma Group Limited ( ASX:MYX ) shares have had a really impressive month, gaining 30% after a shaky period...

Analiz Makalesi • Mar 06

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

The latest analyst coverage could presage a bad day for Mayne Pharma Group Limited ( ASX:MYX ), with the analysts...

Analiz Makalesi • Dec 03

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Market forces rained on the parade of Mayne Pharma Group Limited ( ASX:MYX ) shareholders today, when the analysts...

Analiz Makalesi • Nov 16

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

The results at Mayne Pharma Group Limited ( ASX:MYX ) have been quite disappointing recently and CEO Scott Richards...

Analiz Makalesi • Nov 10

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Kazanç ve Gelir Büyüme Tahminleri

ASX:MYX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2029	397	-22	28	43	1
6/30/2028	389	-38	29	37	2
6/30/2027	379	-46	14	23	2
6/30/2026	384	31	11	14	N/A
3/31/2026	395	-26	5	18	N/A
12/31/2025	407	-82	-1	22	N/A
9/30/2025	408	-86	-6	20	N/A
6/30/2025	408	-90	-12	17	N/A
3/31/2025	411	-104	-12	9	N/A
12/31/2024	414	-118	-12	0	N/A
9/30/2024	401	-143	-24	-7	N/A
6/30/2024	388	-169	-36	-15	N/A
12/31/2023	319	-274	-34	-15	N/A
9/30/2023	251	-296	-148	-29	N/A
6/30/2023	184	-317	-262	-43	N/A
12/31/2022	59	-257	-287	-64	N/A
9/30/2022	108	-233	-153	-36	N/A
6/30/2022	157	-209	-19	-7	N/A
3/31/2022	250	-151	-13	3	N/A
12/31/2021	342	-93	-7	13	N/A
9/30/2021	372	-151	14	36	N/A
6/30/2021	401	-208	34	59	N/A
3/31/2021	420	-232	56	82	N/A
12/31/2020	439	-256	78	106	N/A
9/30/2020	448	-174	72	109	N/A
6/30/2020	457	-93	65	113	N/A
3/31/2020	467	-196	N/A	109	N/A
12/31/2019	478	-300	N/A	106	N/A
9/30/2019	502	-290	N/A	106	N/A
6/30/2019	525	-279	N/A	107	N/A
3/31/2019	543	-118	N/A	117	N/A
12/31/2018	561	43	N/A	127	N/A
9/30/2018	546	-46	N/A	124	N/A
6/30/2018	530	-134	N/A	121	N/A
3/31/2018	526	-146	N/A	111	N/A
12/31/2017	521	-158	N/A	100	N/A
9/30/2017	547	-35	N/A	42	N/A
6/30/2017	573	89	N/A	-15	N/A
3/31/2017	504	90	N/A	-30	N/A
12/31/2016	435	91	N/A	-44	N/A
9/30/2016	351	64	N/A	5	N/A
6/30/2016	267	37	N/A	54	N/A
3/31/2016	238	30	N/A	49	N/A
12/31/2015	209	23	N/A	44	N/A
9/30/2015	175	15	N/A	33	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MYX şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -57.5% ).

Kazançlar ve Piyasa: MYX şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -57.5% ).

Yüksek Büyüme Kazançları: MYX şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor.

Gelir ve Pazar: MYX şirketinin gelirinin (yıllık 1.1% ) Australian pazarından (yıllık 5.3% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MYX şirketinin gelirinin (yıllık 1.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MYX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/10 12:51
Gün Sonu Hisse Fiyatı	2026/09/10 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2026/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Mayne Pharma Group Limited 5 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
William Dunlop	BofA Global Research
Madeleine Williams	Canaccord Genuity
John Deakin-Bell	Citigroup Inc

Mayne Pharma Group Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall from profit to AU$0.50 loss

Price target decreased by 20% to AU$4.62

Price target increased by 9.6% to AU$6.68

Mayne Pharma Group Limited Provides Earnings Guidance for the First Half Ended 31 December 2024

Consensus EPS estimates upgraded to AU$0.18 loss, revenue downgraded

Price target decreased by 12% to AU$6.09

Recent updates

Consensus EPS estimates fall from profit to AU$0.50 loss

Full year 2026 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Profitability

Mayne Pharma Group Limited to Report Fiscal Year 2026 Results on Aug 27, 2026

New minor risk - Profitability

Mayne Pharma Group Limited Announces Appointment of Griffin D. Buchanan as Chief Financial Officer, Effective August 1, 2026

Women’s Health Expansion And Manufacturing Upgrade Will Support Stronger Long-Term Earnings Potential

Price target decreased by 20% to AU$4.62

Rising Women's Health Costs And Flat Revenue Will Eventually Reveal Underappreciated Earnings Potential

None

Women’s Health Trends And Dermatology Platform Will Reshape Long-Term Earnings Profile

Insufficient new directors

Mayne Pharma Group Limited Announces CEO Changes

Mayne Pharma Group Limited to Report First Half, 2026 Results on Feb 23, 2026

Mayne Pharma Receives Notice of Appeal Filed by Cosette and Its Bidco with the Supreme Court of New South Wales, Court of Appeal

Mayne Pharma Group Limited Announces Board Changes Effective January 14, 2026

Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026

New minor risk - Share price stability

Insufficient new directors

New minor risk - Profitability

Full year 2025 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Mayne Pharma Group Limited to Report Fiscal Year 2025 Results on Aug 29, 2025

New minor risk - Profitability

TherapeuticsMD, Inc. Files Lawsuit Against Mayne Pharma for Contract Breaches

First half 2025 earnings released: AU$0.25 loss per share (vs AU$0.88 loss in 1H 2024)

Price target increased by 9.6% to AU$6.68

Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million.

New minor risk - Share price stability

Mayne Pharma Group Limited (ASX:MYX) Held Back By Insufficient Growth Even After Shares Climb 26%

Mayne Pharma Group Limited Provides Earnings Guidance for the First Half Ended 31 December 2024

Consensus EPS estimates upgraded to AU$0.18 loss, revenue downgraded

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Price target decreased by 12% to AU$6.09

New major risk - Financial position

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

New minor risk - Profitability

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023